Hematuria reduction in patients with IgAN following Nefecon treatment: A secondary analysis of the full 2-year NeflgArd Phase 3 trial results

11:15-12:15, September 30, 2023 (JST)

Tokyo, Japan

Authors: <u>Richard Lafayette¹</u>, Jens Kristensen², Andrew Stone³, Jürgen Floege⁴, Vladimir Tesar⁵, Hernán Trimarchi⁶, Hong Zhang⁷, Necmi Eren⁸, Alexander Paliege⁹, Heather N. Reich¹⁰, Brad H. Rovin¹¹, and Jonathan Barratt¹², on behalf of the NeflgArd trial investigators Affiliations: ¹Division of Nephrology, Department of Medicine, Stanford University, Stanford, CA, USA; ²Calliditas Therapeutics AB, Stockholm, Sweden; ³Stone Biostatistics Ltd., Crewe, UK; ⁴Department of Nephrology and Clinical Immunology, Rheinisch Westfälische Technische Hochschule Aachen University Hospital, Aachen, Germany; ⁵Department of Nephrology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic; ⁶Nephrology Service, Hospital Británico de Buenos Aires, Buenos Aires, Argentina; ⁷Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China; ⁸Department of Nephrology, Kocaeli University, Kocaeli, Turkey; ⁹Division of Nephrology, Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universitä Dresden, Dresden, Germany; ¹⁰Division of Nephrology, University Health Network, Department of Medicine, University of Toronto, ON, Canada; ¹¹Division of Nephrology, The Ohio State University Wexner Medical Center, Columbus, OH, USA; ¹²College of Medicine Biological Sciences and Psychology, University of Leicester, Leicester, UK

Date of preparation: September 2023 **Nefecon has not been approved by the Japanese Pharmaceuticals and Medical Devices Agency.**



The 17th International Symposium on IgA Nephropathy

COI disclosure presenter : Richard Lafayette

I have the following relationships to disclose any COI for this research presentation within the period of 36 months.

- * Employment/Leadership position/Advisory role: Calliditas Therapeutics
- * Stock ownership or options:
- * Patent royalties/licensing fees:
- * Honoraria (e.g. lecture fees):
- * Manuscript fees:
- * Research funding: Calliditas Therapeutics
- * Subsidies or donations:
- * Endowed departments by commercial entities:
- * Travel fees, gifts, and others:

Introduction

- Nefecon is a novel, oral, targeted-release budesonide formulation specifically designed to treat IgAN by inhibiting IgA formation in the Peyer's-patch—rich distal ileum^{1,2}
- An interim analysis of the Phase 3 NefIgArd trial (N=199) demonstrated that Nefecon reduced proteinuria (27%, p=0.0003) and had an eGFR treatment benefit of 3.87 mL/min/1.73 m² compared with placebo after 9 months²
 - These findings led to FDA and EMA approval of Nefecon in patients with primary IgAN^{3,4}
- Changes in microhematuria can be measured to determine the efficacy of IgAN treatments⁵
- Here, we present results from a secondary analysis of microhematuria data from the complete 2-year NefIgArd study (N=364)

eGFR, estimated glomerular filtration rate; EMA, European Medicines Agency; FDA, Food and Drug Administration; IgAN, immunoglobulin A nephropathy. 1. Barratt J, *et al. Kidney Int Rep* 2020;5:1620-1624. 2. Barratt J, *et al. Kidney Int* 2023;103:391-402. 3. Calliditas Therapeutics AB. Tarpeyo (Nefecon) US PI. 2021. <u>https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215935s000lbl.pdf</u> (accessed September 2023). 4. STADA Arzneimittel. Kinpeygo (Nefecon) SmPC. 2023. <u>https://www.ema.europa.eu/en/medicines/human/EPAR/kinpeygo</u> (accessed September 2023). 5. Coppo R & Fervenza FC. *J Am Soc Nephrol* 2017;28:2831-2834.

Methods

NeflgArd: A Phase 3, two-part, randomized, double-blind, placebo-controlled study


Aim of the analysis: To assess the effect of Nefecon 16 mg/day on microhematuria in patients with IgAN over the 9-month treatment period and 15-month observational follow-up period of the Phase 3 NeflgArd trial

Key inclusion criteria:

- ≥18 years old with biopsy-confirmed primary IgAN
- UPCR ≥0.8 g/g or proteinuria ≥1 g/24h, despite optimized RAS inhibition
- eGFR 35-90 mL/min/1.73 m²

Key exclusion criteria

- Secondary form of IgAN or non-IgAN glomerulonephritis
- Kidney transplant
- Systemic diseases that may cause mesangial IgA deposition
- Poorly controlled BP (≥140/90 mmHg)
- Poorly controlled T1D or T2D



899

Primary efficacy endpoint: Time-weighted average of eGFR over 2 years

Secondary efficacy endpoint: Proportion of patients without microhematuria* in at least 2 follow-up visits at 12, 18, and 24 months

*A patient was defined as without microhematuria if the urine dipstick returned a result of negative or trace. The proportion of patients without microhematuria was analyzed using a logistic regression model including treatment, log-baseline UPCR, log-baseline eGFR, and geographic region as covariates. Patients without at least two valid results from 12 months onwards were excluded from the analysis. BP, blood pressure; eGFR, estimated glomerular filtration rate; IgA, immunoglobulin A; IgAN, immunoglobulin A nephropathy; RAS, renin–angiotensin system; T1D, type 1 diabetes; T2D, type 2 diabetes; UPCR, urine protein-creatinine ratio.

Baseline characteristics

	Nefecon 16 mg (n=182)	Placebo (n=182)
Age, years, median (range)	43 (21-69)	42 (20-73)
Sex, male, n (%)	117 (64.3)	123 (67.6)
Race, White, n (%)	138 (75.8)	137 (75.3)
Race, Asian, n (%)	43 (23.6)	40 (22.0)
Systolic BP, median (IQR)	126 (121-132)	124 (117-130)
Diastolic BP, median (IQR)	79 (76-84)	79 (74-84)
UPCR, g/gram, median (IQR)	1.28 (0.90-1.76)	1.25 (0.88-1.74)
eGFR CKD-EPI, mL/min/1.73 m ² , median (IQR)	56.1 (45.5-71.0)	55.1 (46.0-67.7)


BP, blood pressure; CKD-EPI, Chronic Kidney Disease-Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; IQR, interquartile range; UPCR, urine protein-creatinine ratio.

Primary endpoint: Time-weighted eGFR change

For additional details on the primary results from NeflgArd please scan here:



Primary endpoint: Time-weighted average change from baseline in eGFR over the 2-year period



- eGFR treatment benefit of 5.05 (95% CI 3.24, 7.38) mL/min/1.73 m² with Nefecon 16 mg/day vs placebo (p<0.0001)
- eGFR benefit of Nefecon observed by 9 months of treatment was maintained over 15 months of observational follow-up


Error bars represent standard error.

CI, confidence interval; eGFR, estimated glomerular filtration rate.

Secondary endpoint: Change in UPCR



Mean percentage change in UPCR from baseline




30% reduction in UPCR with Nefecon compared with placebo observed after the 9-month treatment period **sustained up to 2 years**

Error bars represent standard error.

CI, confidence interval; UPCR, urine protein-creatinine ratio.

Secondary endpoint: eGFR benefit by baseline UPCR






Error bars represent standard error.

eGFR, estimated glomerular filtration rate; UPCR, urine protein-creatinine ratio.

Secondary endpoint: Proportion of patients without microhematuria

Proportion of patients without microhematuria at different time points during observational follow-up



Of the 364 patients in the full analysis set, 158/182 patients in the Nefecon group and 152/182 patients in the placebo group had at least two valid urine dipstick results during the observational follow-up period. Cl, confidence interval; OR, odds ratio.

Conclusions

- Patients receiving 9 months of Nefecon treatment were significantly less likely than those receiving placebo to have microhematuria up to 15 months after the end of treatment
 - The proportion of patients without microhematuria was 59.5% versus 38.8% (p=0.0001) during the observational follow-up for Nefecon and placebo, respectively
- These results may be due to a reduction in IgA immune complex-mediated inflammation in the glomeruli with Nefecon and provide further evidence for the disease-modifying effect of Nefecon